Drug Profile
PRV 101
Alternative Names: Coxsackievirus B vaccine - Provention Bio; Polyvalent coxsackievirus B vaccine; PRV-101; Type 1 diabetes vaccine - Provention BioLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Vactech
- Developer Provention Bio; Vactech
- Class Antibodies; Enterovirus vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Coeliac disease
- No development reported Coxsackievirus infections; Type 1 diabetes mellitus
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Coxsackievirus-infections(Prevention, In volunteers) in Finland (IM, Injection)
- 27 Apr 2023 Provention Bio has been acquired by Sanofi
- 28 May 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus(Prevention) in USA (Parenteral)